ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

SABSW SAB Biotherapeutics Inc

0.035
0.0046 (15.13%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
SAB Biotherapeutics Inc SABSW NASDAQ Warrant Capital Accionario
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0046 15.13% 0.035 18:50:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.035 0.035 0.035 0.035 0.0304
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202406:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08/4/202406:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04/4/202406:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29/3/202406:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
25/3/202409:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
23/2/202407:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
08/2/202407:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02/2/202406:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
23/1/202416:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
02/1/202415:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
29/11/202306:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
20/11/202306:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
14/11/202306:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14/11/202306:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
09/11/202306:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
24/10/202306:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
19/10/202306:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05/10/202306:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
02/10/202306:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
21/8/202307:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
21/6/202307:30GLOBESAB Biotherapeutics Presents Positive IND-Enabling GLP..
30/5/202307:30GLOBESAB Biotherapeutics to Present Novel Human IgG Platform with..
19/5/202307:30GLOBESAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio..
16/5/202307:30GLOBESAB Biotherapeutics Provides Company Update for Q1 2023..
12/5/202307:30GLOBESAB Biotherapeutics Announces First Publication of Promising..
09/5/202307:30GLOBESAB Biotherapeutics Announces Progress on U.S. FDA’s Phased..
04/5/202307:30GLOBESAB Biotherapeutics Presents Positive Phase 1 and 2a Data..
03/5/202316:00GLOBESAB Biotherapeutics to Present at Sidoti Virtual Investor..

Su Consulta Reciente

Delayed Upgrade Clock